---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013590"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:45:57.031387+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Capricor reports Q2 net loss $7.4M; HOPE-3 DMD trial on track for Q4 2023 interim analysis

## Summary
- Cash, equivalents & marketable securities $37.8M as of June 30, down from $41.4M Dec 31, 2022.
- Q2 revenue $3.9M from Nippon Shinyaku upfront recognition vs. $0 in prior year; operating expenses $11.7M vs $7.3M.
- HOPE-3 Phase 3 DMD trial: 48 of ~68 patients randomized across 17 sites; enrollment completion and interim analysis expected Q4 2023.
- Held FDA Type-B clinical meeting to discuss CAP-1002 BLA pathway; final minutes awaited.
- Raised ~$2.1M net via ATM at avg $4.87/share; cash runway through Q3 2024.

## SEC filing metadata
- accession: 0001558370-23-013590
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/0001558370-23-013590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/capr-20230807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013590
- JSON: https://secwatch.observer/filing/0001558370-23-013590.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013590.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/0001558370-23-013590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.